$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

$sls Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-Q Financial Statement

#000139047817000074 Filed on November 09, 2017

Income Statement

Concept	2017 Q4	2017 Q3	2016 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.990M	$3.222M	-$4.900M
YoY Change	-222.24%	13.13%	-278.83%
% of Gross Profit
Research & Development	$710.0K	$1.068M	-$3.850M
YoY Change	-118.44%	-70.53%	-179.38%
% of Gross Profit
Depreciation & Amortization	$0.00	$30.00K	-$100.0K
YoY Change	-100.0%	0.0%	-47.37%
% of Gross Profit
Operating Expenses	$8.580M	$4.290M	-$8.740M
YoY Change	-198.17%	-33.71%	-215.15%
Operating Profit		-$4.462M
YoY Change		-31.06%
Interest Expense	-$6.060M	-$100.0K	-$13.35M
YoY Change	-54.61%	-104.39%	-770.85%
% of Operating Profit
Other Income/Expense, Net	$180.0K	-$4.392M	-$5.710M
YoY Change	-103.15%	2828.0%	-1397.73%
Pretax Income	-$7.920M	-$4.390M	-$8.510M
YoY Change	-6.93%	1.15%	-18.49%
Income Tax	$250.0K	$63.00K	$0.00
% Of Pretax Income
Net Earnings	$2.440M	-$4.455M	$350.0K
YoY Change	597.14%	-35.71%	-101.78%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.15
Diluted Earnings Per Share	$20.33M	-$111.5M	$5.833M
COMMON SHARES
Basic Shares Outstanding	45.71M shares	39.25M shares	217.0M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q4	2017 Q3	2016 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.300M	$12.90M	$6.000M
YoY Change	-61.67%	-47.35%	-79.8%
Cash & Equivalents	$2.319M	$12.90M	$5.962M
Short-Term Investments
Other Short-Term Assets	$10.70M	$13.70M	$400.0K
YoY Change	2575.0%	-31.16%	-98.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$0.00
Total Short-Term Assets	$13.09M	$26.64M	$6.379M
YoY Change	105.16%	-40.09%	-88.1%
LONG-TERM ASSETS
Property, Plant & Equipment		$123.0K	$199.0K
YoY Change		-45.58%	-40.6%
Goodwill	$1.914M	$5.386M	$5.898M
YoY Change	-67.55%	-8.68%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$900.0K	$100.0K	$0.00
YoY Change		0.0%	-100.0%
Total Long-Term Assets	$20.44M	$22.96M	$41.00K
YoY Change	49751.22%	-19.12%	-99.86%
TOTAL ASSETS
Total Short-Term Assets	$13.09M	$26.64M	$6.379M
Total Long-Term Assets	$20.44M	$22.96M	$41.00K
Total Assets	$33.53M	$49.60M	$6.420M
YoY Change	422.21%	-31.92%	-92.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.69M	$211.0K	$840.0K
YoY Change	1291.79%	-76.4%	-47.4%
Accrued Expenses	$3.201M	$3.186M	$4.049M
YoY Change	-20.94%	-16.58%	-23.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$8.377M	$12.17M	$16.40M
YoY Change	-48.91%	-48.7%	246.0%
Total Short-Term Liabilities	$24.57M	$28.02M	$5.758M
YoY Change	326.69%	-34.13%	-89.91%
LONG-TERM LIABILITIES
Long-Term Debt	$2.611M	$0.00	$5.700M
YoY Change	-54.19%
Other Long-Term Liabilities	$2.600M	$1.300M	$0.00
YoY Change		30.0%	-100.0%
Total Long-Term Liabilities	$2.611M	$1.300M	$5.700M
YoY Change	-54.19%	30.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.57M	$28.02M	$5.758M
Total Long-Term Liabilities	$2.611M	$1.300M	$5.700M
Total Liabilities	$31.46M	$34.96M	$11.42M
YoY Change	175.52%	-28.53%	-83.36%
SHAREHOLDERS EQUITY
Retained Earnings	-$54.19M	-$329.1M	-$30.43M
YoY Change	78.06%
Common Stock	$56.26M	$347.6M	$25.44M
YoY Change	121.16%	6.89%	-91.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$3.849M	$3.849M
YoY Change		0.0%	0.0%
Treasury Stock Shares		33.75K shares	33.75K shares
Shareholders Equity	$2.070M	$14.64M	-$4.997M
YoY Change
Total Liabilities & Shareholders Equity	$33.53M	$49.60M	$6.420M
YoY Change	422.21%	-31.92%	-92.18%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2016 Q4
OPERATING ACTIVITIES
Net Income	$2.440M	-$4.455M	$350.0K
YoY Change	597.14%	-35.71%	-101.78%
Depreciation, Depletion And Amortization	$0.00	$30.00K	-$100.0K
YoY Change	-100.0%	0.0%	-47.37%
Cash From Operating Activities	-$1.740M	-$2.400M	$25.07M
YoY Change	-106.94%	-80.34%	-264.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$12.16M		$960.0K
YoY Change	1166.67%		-91.5%
Cash From Investing Activities	$12.16M		$970.0K
YoY Change	1153.61%		-91.35%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-120.0K	-10.00K	-16.26M
YoY Change	-99.26%	-100.06%	1526.0%
NET CHANGE
Cash From Operating Activities	-1.740M	-2.400M	25.07M
Cash From Investing Activities	12.16M		970.0K
Cash From Financing Activities	-120.0K	-10.00K	-16.26M
Net Change In Cash	10.30M	-2.410M	9.780M
YoY Change	5.32%	-148.88%	-293.28%
FREE CASH FLOW
Cash From Operating Activities	-$1.740M	-$2.400M	$25.07M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001390478
CY2017Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	45712912	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Galena Biopharma, Inc.
	dei	Trading Symbol TradingSymbol	GALE
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	14172000	USD
	gale	Change In Fair Value Of Common Stock Warrants Issued In Connection With Various Equity Financings ChangeInFairValueOfCommonStockWarrantsIssuedInConnectionWithVariousEquityFinancings	7822000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	5182000	USD
	gale	Change In Fair Value Of Contingent Purchase Consideration ChangeInFairValueOfContingentPurchaseConsideration	-182000	USD
CY2016Q3	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-145000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	5182000	USD
CY2017Q3	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-50000	USD
	gale	Change In Fair Value Of Contingent Purchase Price Consideration ChangeInFairValueOfContingentPurchasePriceConsideration	-182000	USD
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Senior Management EstimatedAnnualizedForfeitureRateForOptionsGrantedToSeniorManagement	0.08
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	0	USD
	gale	Fair Value Of Parent Company Common Stock Issued In Exchange For Services FairValueOfParentCompanyCommonStockIssuedInExchangeForServices	123000	USD
	gale	Fair Value Of Warrants Exercised FairValueOfWarrantsExercised	0	USD
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	9866000	USD
	gale	Classof Warrantor Right Expired ClassofWarrantorRightExpired	13000	shares
	gale	Change In Fair Value Of Warrant Liabilities ChangeInFairValueOfWarrantLiabilities	-7822000	USD
	gale	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	0	shares
	gale	Estimated Annualized Forfeiture Rate For Options Granted To Employees EstimatedAnnualizedForfeitureRateForOptionsGrantedToEmployees	0.15
	gale	Fair Value Of Warrants Issued In Connection With Common Stock Recorded As Cost Of Equity FairValueOfWarrantsIssuedInConnectionWithCommonStockRecordedAsCostOfEquity	10357000	USD
	gale	Classof Warrantor Right Granted ClassofWarrantorRightGranted	17000000	shares
CY2016	gale	Classof Warrantor Right Term ClassofWarrantorRightTerm	P5Y
CY2017Q3	gale	Common Stock Capital Shares Reserved For Future Issuance Of Employee Stock Purchase Plan CommonStockCapitalSharesReservedForFutureIssuanceOfEmployeeStockPurchasePlan	17000	shares
CY2016Q4	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	1095000	USD
CY2017Q3	gale	Contingent Purchase Price Consideration Net Of Current Portion ContingentPurchasePriceConsiderationNetOfCurrentPortion	1277000	USD
CY2016Q4	gale	Contract Research Payable ContractResearchPayable	3088000	USD
CY2017Q3	gale	Contract Research Payable ContractResearchPayable	324000	USD
CY2017Q3	gale	Debt Instrument Covenant Liquidity Covenant DebtInstrumentCovenantLiquidityCovenant	12000000	USD
	gale	Debt Instrument Redemption Principal Amount Redeemed DebtInstrumentRedemptionPrincipalAmountRedeemed	5650000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs EmployeeServiceShareBasedCompensationUnrecognizedCompensationCosts	600000	USD
	gale	Employee Service Share Based Compensation Unrecognized Compensation Costs Weighted Average Period Of Recognition EmployeeServiceShareBasedCompensationUnrecognizedCompensationCostsWeightedAveragePeriodOfRecognition	P2Y2M9D
CY2016Q4	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	1860000	USD
CY2017Q3	gale	Fair Value Of Warrants Liabilities FairValueOfWarrantsLiabilities	4395000	USD
CY2016Q4	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	1860000	USD
CY2017Q3	gale	Fair Value Of Warrants Potentially Settleable In Cash FairValueOfWarrantsPotentiallySettleableInCash	4395000	USD
	gale	Fair Valueof Warrants Granted FairValueofWarrantsGranted	10357000	USD
CY2013Q2	gale	Fair Valueof Warrants Grantedper Share FairValueofWarrantsGrantedperShare	38.60
	gale	Fair Valueof Warrants Issuedin Connectionwith Long Term Debt Recordedas Debt Issuance Costs FairValueofWarrantsIssuedinConnectionwithLongTermDebtRecordedasDebtIssuanceCosts	1139000	USD
CY2016Q4	gale	Gale401rights GALE401rights	9255000	USD
CY2017Q3	gale	Gale401rights GALE401rights	8100000	USD
CY2016Q4	gale	In Process Research Development InProcessResearchDevelopment	12864000	USD
CY2017Q3	gale	In Process Research Development InProcessResearchDevelopment	9300000	USD
	gale	Increase Decreasein Restricted Cashfor Financing Activities IncreaseDecreaseinRestrictedCashforFinancingActivities	0	USD
	gale	Increase Decreasein Restricted Cashfor Financing Activities IncreaseDecreaseinRestrictedCashforFinancingActivities	-5650000	USD
CY2016Q3	gale	Intangible Assets Rights Impairment Charge IntangibleAssetsRightsImpairmentCharge	0	USD
	gale	Intangible Assets Rights Impairment Charge IntangibleAssetsRightsImpairmentCharge	0	USD
CY2017Q3	gale	Intangible Assets Rights Impairment Charge IntangibleAssetsRightsImpairmentCharge	1155000	USD
	gale	Intangible Assets Rights Impairment Charge IntangibleAssetsRightsImpairmentCharge	1155000	USD
CY2016Q3	gale	Loss On Warrant Exchange LossOnWarrantExchange	-3652000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	-14172000	USD
CY2017Q3	gale	Loss On Warrant Exchange LossOnWarrantExchange	-4115000	USD
	gale	Loss On Warrant Exchange LossOnWarrantExchange	-7822000	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	233000	USD
	gale	Net Proceeds From Exercise Of Common Stock Warrants NetProceedsFromExerciseOfCommonStockWarrants	0	USD
CY2017Q3	gale	Options Reserved For Future Issuance Under Companies Incentive Plan OptionsReservedForFutureIssuanceUnderCompaniesIncentivePlan	457000	shares
	gale	Paymentof Cash Dividendsfor Covenanton Longterm Debt PaymentofCashDividendsforCovenantonLongtermDebt	18500000	USD
	gale	Paymentof Cash Dividendsfor Covenanton Longterm Debt PaymentofCashDividendsforCovenantonLongtermDebt	0	USD
	gale	Paymentson Disposalof Productive Assets PaymentsonDisposalofProductiveAssets	1050000	USD
	gale	Reclassification Of Warrant Liability Upon Exercise ReclassificationOfWarrantLiabilityUponExercise	324000	USD
CY2016Q3	gale	Research And Development In Process Impairment ResearchAndDevelopmentInProcessImpairment	0	USD
	gale	Research And Development In Process Impairment ResearchAndDevelopmentInProcessImpairment	0	USD
CY2017Q3	gale	Research And Development In Process Impairment ResearchAndDevelopmentInProcessImpairment	3564000	USD
	gale	Research And Development In Process Impairment ResearchAndDevelopmentInProcessImpairment	3564000	USD
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriodIntrinsicValue	0	USD
CY2016Q4	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	100000	shares
	gale	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateAggregateIntrinsicValue		USD
CY2017Q3	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	15000	shares
CY2013Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	9109	shares
CY2016Q2	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	50000	shares
CY2016Q3	gale	Warrants Granted Numberof Shares WarrantsGrantedNumberofShares	50000	shares
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	840000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	211000	USD
	us-gaap	Accretion Expense AccretionExpense	1280000	USD
	us-gaap	Accretion Expense AccretionExpense	1423000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4292000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3186000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	229000	USD
CY2017Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1827000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	335436000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	347610000	USD
	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	356000	USD
	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	576000	USD
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	10357000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3088000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	20000000	shares
CY2016Q4	us-gaap	Assets Assets	65811000	USD
CY2017Q3	us-gaap	Assets Assets	49595000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	37499000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	26636000	USD
CY2016Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	813000	USD
CY2017Q3	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	830000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29730000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24514000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18083000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12914000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12900000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5216000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-5169000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-1050000	USD
	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	0	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-9155000	USD
	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-9937000	USD
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	79.40
CY2017Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	79.40
CY2013Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	49.40
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.60
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	30.20
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.60
CY2016Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	2570000	shares
CY2017Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	19557000	shares
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	95000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	76000	USD
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.76
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	975000	USD
CY2017Q3	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	198357	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5661000	USD
CY2017Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5661000	USD
CY2016Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	96000	USD
CY2017Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	50000	USD
CY2017Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	20474000	shares
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15224223	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41849725	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15190473	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41815975	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	2000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	4000	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	0	USD
	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	6305000	USD
	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	7806708	shares
CY2016Q3	us-gaap	Costs And Expenses CostsAndExpenses	6472000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	24732000	USD
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	4462000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	14461000	USD
CY2016Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	17621702	USD
CY2017Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	11971702	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1224672	USD
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.66
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.90
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.15
CY2017Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1035000	USD
CY2013Q2	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016Q3	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2013Q2	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P7D
CY2016Q3	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y6M
CY2016	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P5Y6M
CY2013Q2	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7534
CY2016Q3	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	1.0663
CY2016	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.7713
CY2013Q2	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0120
CY2016Q3	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0135
CY2016	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0126
	us-gaap	Interest Expense InterestExpense	765000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.31
CY2016Q4	us-gaap	Goodwill Goodwill	5898000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	5386000	USD
CY2016Q3	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0	USD
CY2017Q3	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	5231000	USD
	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	5231000	USD
CY2016Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	512000	USD
CY2017Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	500000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	512000	USD
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	0	USD
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	512000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	4719000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-4342000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-9166000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-6193000	USD
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-15577000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.41
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.97
CY2017Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.15
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.45
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-2587000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-8867000	USD
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	118000	USD
	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-10620000	USD
CY2016Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.25
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.93
CY2017Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0.00
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-703000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-629000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1473000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1106000	USD
	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	288000	USD
	us-gaap	Increase Decrease In Assets Held For Sale IncreaseDecreaseInAssetsHeldForSale	-683000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	-25000000	USD
	us-gaap	Increase Decrease In Insurance Liabilities IncreaseDecreaseInInsuranceLiabilities	350000	USD
	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	-21700000	USD
	us-gaap	Increase Decrease In Insurance Settlements Receivable IncreaseDecreaseInInsuranceSettlementsReceivable	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-381000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-107000	USD
CY2016Q4	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	9255000	USD
CY2017Q3	us-gaap	Indefinite Lived Contractual Rights IndefiniteLivedContractualRights	8100000	USD
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	22119000	USD
CY2017Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	17400000	USD
	us-gaap	Interest Expense InterestExpense	0	USD
CY2016Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1377000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1988000	USD
CY2017Q3	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2017Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-565000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-2225000	USD
	us-gaap	Interest Paid InterestPaid	636000	USD
	us-gaap	Interest Paid InterestPaid	102000	USD
CY2016Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2016Q4	us-gaap	Liabilities Liabilities	37154000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	34959000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	65811000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49595000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	30398000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	28021000	USD
CY2016Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	6059000	USD
CY2017Q3	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	6759000	USD
CY2016Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	950000	USD
CY2017Q3	us-gaap	Litigation Reserve Current LitigationReserveCurrent	1300000	USD
CY2016Q3	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	0	USD
	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	-1800000	USD
CY2017Q3	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	0	USD
	us-gaap	Litigation Settlement Amount LitigationSettlementAmount	-1300000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16397030	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16397000	USD
CY2017Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	12170059	USD
CY2017Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	12170000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32755000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	21069000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1056000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-6000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36915000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26238000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-27760000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-16301000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-6929000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18033000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-6075000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26197000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6472000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24732000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4462000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-14461000	USD
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	0	USD
	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3564000	USD
CY2016Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	2130000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	15566000	USD
CY2017Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1731000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-1116000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	223000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	105000	shares
CY2017Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	581000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	520000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	84000	USD
	us-gaap	Proceeds From Interest Received ProceedsFromInterestReceived	83000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	31804000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	15524000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	23641000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	95000	USD
	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	5000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	261000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	199000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	123000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	4779000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	110000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3624000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15242000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	951000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5357000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	18022000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	12372000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-302932000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-329129000	USD
CY2016Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2848000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9490000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3511000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	9104000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1830000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	576000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.0277
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.9891
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.1641
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0123
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0125
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0187
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	285000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	43.76
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	USD
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	5000	USD
	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	123000	USD
	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	15524000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	28657000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	14636000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28657000	USD
CY2017Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	14636000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.15
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	561000	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	443000	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	41.50
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.23
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	0	USD
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	43.01
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.35
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y5M19D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M29D
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y11M1D
	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P10Y
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	6305000	USD
CY2016Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	33750	shares
CY2017Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	33750	shares
CY2016Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2017Q3	us-gaap	Treasury Stock Value TreasuryStockValue	3849000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10465164	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9515316	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39250419	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34406397	shares

Files In Submission

Name	View Source	Status
0001390478-17-000074-index-headers.html	Edgar Link	pending
0001390478-17-000074-index.html	Edgar Link	pending
0001390478-17-000074.txt	Edgar Link	pending
0001390478-17-000074-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gale-20170930.xml	Edgar Link	completed
gale-20170930.xsd	Edgar Link	pending
gale-20170930x10q.htm	Edgar Link	pending
gale-20170930_cal.xml	Edgar Link	unprocessable
gale-20170930_def.xml	Edgar Link	unprocessable
gale-20170930_lab.xml	Edgar Link	unprocessable
gale-20170930_pre.xml	Edgar Link	unprocessable
gale20170930ex311.htm	Edgar Link	pending
gale20170930ex321.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
s4pipelinecopy.jpg	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls

2017 Q4 Form 10-Q Financial Statement

#000139047817000074 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS SELLAS Life Sciences Group, Inc. Stock $sls

2017 Q4 Form 10-Q Financial Statement

#000139047817000074 Filed on November 09, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SLS
SELLAS Life Sciences Group, Inc. Stock $sls